Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred

IMPACT FACTOR 2018: 3.014
5-year IMPACT FACTOR: 3.162

CiteScore 2018: 3.09

SCImago Journal Rank (SJR) 2018: 1.482
Source Normalized Impact per Paper (SNIP) 2018: 0.820

See all formats and pricing
More options …
Volume 392, Issue 3


Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers

Eric Grouzmann / Paul Bigliardi / Monique Appenzeller
  • Division de Pharmacologie et Toxicologie Cliniques, CHU Vaudois, CH-1011 Lausanne, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ André Pannatier / Thierry Buclin
  • Division de Pharmacologie et Toxicologie Cliniques, CHU Vaudois, CH-1011 Lausanne, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-06-18 | DOI: https://doi.org/10.1515/bc.2011.003


Substance P (SP), an undecapeptide belonging to the tachykinin family, is released during the activation of sensory nerves, and causes vasodilation, edema and pain through activation of tissular Neurokinin 1 receptors. SP proinflammatory effects are terminated by angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), while the aminopeptidase dipeptidylpeptidase IV (DPPIV) can also play a role. The aim of this randomized, crossover, double-blind study was to assess the cutaneous vasoreactivity (flare and wheal reaction, burning pain sensation) to intradermal injection of ascending doses of SP in six volunteers receiving a single therapeutic dose of the DPPIV inhibitor sitagliptin or a matching placebo. Cutaneous SP challenges produced the expected, dose-dependent flare and wheal response, while eliciting mild to moderate local pain sensation with little dose dependency. However, no differences were shown in the responses observed under sitagliptin compared with placebo, while the study would have been sufficiently powered to detect a clinically relevant increase in sensitivity to SP. The results of this pilot study are in line with proteolytic cleavage of SP by ACE and NEP compensating the blockade of DPPIV to prevent an augmentation of its proinflammatory action.

Keywords: clinical trial; dipeptidylpeptidase IV; flare; proteases; tachykinin; wheal

About the article

Corresponding author

Received: 2010-07-12

Accepted: 2010-08-23

Published Online: 2011-06-18

Published in Print: 2011-03-01

Citation Information: Biological Chemistry, Volume 392, Issue 3, Pages 217–221, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/bc.2011.003.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Daiji Kawanami, Keiichiro Matoba, Kazunori Sango, and Kazunori Utsunomiya
International Journal of Molecular Sciences, 2016, Volume 17, Number 8, Page 1223
Mayur Kamble, Rachna Gupta, Harmeet S. Rehan, and Lalit K. Gupta
European Journal of Pharmacology, 2016, Volume 774, Page 64
Yuichi Makino, Yukihiro Fujita, and Masakazu Haneda
Current Opinion in Nephrology and Hypertension, 2015, Volume 24, Number 1, Page 67
Shereen O. Tawfic, Iman M. Amin, Rehab A. Hassanein, and Marwa A.E. Moneim Elshaer
Journal of the Egyptian Womenʼs Dermatologic Society, 2013, Volume 10, Number 3, Page 137
Fiorenzo Mignini, Filippo Giovannetti, Mario Cocchioni, Raponi Ingrid, and Giorgio Iannetti
Journal of Craniofacial Surgery, 2012, Volume 23, Number 5, Page 1479
Torsten Hoffmann and Hans-Ulrich Demuth
Biological Chemistry, 2011, Volume 392, Number 3
Sreevidya Subbarayan and Mark Kipnes
Expert Opinion on Pharmacotherapy, 2011, Volume 12, Number 10, Page 1613

Comments (0)

Please log in or register to comment.
Log in